Centre of Research in Epidemiology and Statistics (CRESS), Unité mixte de recherche (UMR) 1153, Institut national de la santé et de la recherche médicale (Inserm), Université de Paris, Paris, France.
Faculté de Pharmacie de Paris, Université de Paris, Paris, France.
Environ Health Perspect. 2019 Oct;127(10):107013. doi: 10.1289/EHP5159. Epub 2019 Oct 30.
The question of whether exposure to bisphenol A (BPA) contributes to the development of type 2 diabetes is still unresolved. Most epidemiological evidence on the association between BPA and diabetes is from cross-sectional studies or longitudinal studies with single urinary measurements. No prospective study has examined exposure to BPA analogs such as bisphenol S (BPS) in relation to incident type 2 diabetes.
We aimed to investigate whether exposure to BPA and BPS, assessed at up to two time points, was associated with the incidence of type 2 diabetes.
We performed a case-cohort study on 755 participants without diabetes at baseline and followed-up over 9 y as part of the French prospective cohort Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.). BPA-glucuronide (BPA-G) and BPS-glucuronide (BPS-G) were assessed in fasting spot urine samples collected during the health examinations at baseline and 3 y later. Associations with incident diabetes were examined using Prentice-weighted Cox regression models adjusted for potential confounders.
A total of 201 incident cases of type 2 diabetes were diagnosed over the follow-up, including 30 in the subcohort. Compared with participants with the lowest average BPA exposure (below the first quartile), participants in the second, third, and fourth quartile groups of exposure had a near doubling of the risk of type 2 diabetes, with a hazard ratio 2.56 (95% CI: 1.16, 5.65), 2.35 (95% CI: 1.07, 5.15), and 1.56 (95% CI: 0.68, 3.55), respectively. The detection of BPS-G in urine at one or both time points was associated with incident diabetes, with an 2.81 (95% CI: 1.74, 4.53).
This study shows positive associations between exposure to BPA and BPS and the incidence of type 2 diabetes, independent of traditional diabetes risk factors. Our results should be confirmed by recent, population-based observational studies in different populations and settings. Overall, these findings raise concerns about using BPS as a BPA substitute. Further research on BPA analogs is warranted. https://doi.org/10.1289/EHP5159.
双酚 A(BPA)暴露是否会导致 2 型糖尿病的发生仍未得到解决。大多数关于 BPA 与糖尿病之间关联的流行病学证据来自于横断面研究或仅有单次尿样测量的纵向研究。没有前瞻性研究检查过 BPA 类似物(如双酚 S,BPS)的暴露与 2 型糖尿病发病之间的关系。
我们旨在研究 BPA 和 BPS 的暴露情况,这些暴露情况是通过在基线时和之后的 9 年内进行的两次检测来评估的,与 2 型糖尿病的发病是否有关。
我们在法国前瞻性队列研究中开展了一项病例对照研究,该研究的部分内容为“胰岛素抵抗综合征的流行病学研究(D.E.S.I.R.)”。在基线健康检查时和 3 年后的随访中,收集了空腹点尿样,以检测 BPA-葡糖苷酸(BPA-G)和 BPS-葡糖苷酸(BPS-G)。使用 Prentice 加权 Cox 回归模型调整了潜在混杂因素后,评估了这些暴露与新发糖尿病之间的关联。
在随访期间共诊断出 201 例 2 型糖尿病病例,其中包括亚组中的 30 例。与暴露于最低平均 BPA(低于第一四分位数)的参与者相比,暴露于第二、第三和第四四分位数的参与者患 2 型糖尿病的风险增加了近一倍,风险比分别为 2.56(95%CI:1.16,5.65)、2.35(95%CI:1.07,5.15)和 1.56(95%CI:0.68,3.55)。在一个或两个时间点检测到 BPS-G 在尿液中存在,与新发糖尿病相关,风险比为 2.81(95%CI:1.74,4.53)。
本研究表明,BPA 和 BPS 的暴露与 2 型糖尿病的发病之间存在正相关,这与传统的糖尿病危险因素无关。我们的结果应在不同人群和环境的基于人群的最新观察性研究中得到证实。总的来说,这些发现引起了人们对使用 BPS 作为 BPA 替代品的关注。需要进一步研究 BPA 类似物。